1. Pink Sheet
  2. >>Archive

FDA's Cleveland Clinic and Duke Connection

 
• By Cole Werble

Steven Nissen (Cleveland Clinic) and Robert Califf (Duke) are well known advisers to FDA: outside experts the agency turns to on thorny issues -- especially involving cardiovascular risks. What is less recognized is the prominence of the institutions that Nissen and Califf represent and their impact on the FDA advisory committee process. The agency currently has a dozen advisory committee members from the Cleveland Clinic and Duke.

When the Food & Drug Administration took on the thorny subjects of how and when to conduct cardiovascular outcomes research for diabetes drugs at a public advisory committee earlier this summer, the agency devoted half a day to presentations by two of the most prominent academic experts on clinical trials for cardiovascular events: Cleveland Clinic medical director Steven Nissen and Duke University vice chancellor for medical research, Robert Califf.

It wasn’t surprising for FDA to turn to Nissen and Califf for help on the tough subject of changing clinical...

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 
• By Neena Brizmohun

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Nielsen Hobbs

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Nielsen Hobbs

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 
• By Francesca Bruce

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 
• By Sarah Karlin-Smith

The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

Clinical Trial Diversity Action Plan Guidance Must Return To US FDA Website, Court Says

 
• By Sue Sutter

HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.

Industry Groups Back EU Life Sciences Strategy As Commission Pledges Clinical Trial Investment

 
• By Eliza Slawther

Industry associations EFPIA, EUCOPE and EURORDIS have praised the European Commission’s newly launched life sciences strategy, which will see investment funnelled into improving the clinical trial ecosystem and supporting advanced therapy development.